Estrogen receptor is the specific target for endocrine therapy, and ESR1 mutations can be selected by prior aromatase inhibitor therapy in advanced breast cancer, influencing the sensitivity of standard endocrine therapies. This evidence concerns the gene ESR1 and breast carcinoma.